Edmonton, Canada, November 7 (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A summary of the results is as follows: - All primary and secondary efficacy endpoints were achieved at 24 weeks - Efficacy endpoints were ...
International Bureau for Epilepsy (IBE) & UCB
Sydney, November 7 (ots/PRNewswire) - - With Photos The first live performance of Brain Storm, a theatre production focused on epilepsy was staged today at the 2005 World Congress of Neurology in Sydney, Australia. Brain Storm dramatizes the devastating effect that uncontrolled seizures can have on the ...
Edmonton, Canada, November 4 (ots/PRNewswire) - - ATTN: Business/Assignment Editors: EDMONTON, Canada, November 4 /PRNewswire/ -- Isotechnika Inc. will announce the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247 on Monday, November 7th at 7:00 a.m. EST/5:00a.m. MST. Management will ...
Paris, November 2 (ots/PRNewswire) - The European School of Oncology (ESO) presented this year's joint winners of the ACE (Awarding Cancer Enlightenment) Reporter Award 2005 -- Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Nepszabadsag, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima -- with euro 5,000 each at an award ceremony held today at the European ...
Bunnik, The Netherlands (ots/PRNewswire) - - Three Lead Compounds are Progressing Into Next Clinical Phase AM-Pharma B.V., a privately owned biopharmaceutical company, engaged in the pre-clinical and early clinical development of novel compounds to treat infectious and inflammatory diseases and their consequences, announces that a major B-financing round has been successfully completed. The company attracted ...
Basel, Switzerland (ots/PRNewswire) - The news that the innovative new cancer drug Tarceva(R) (erlotinib) is now becoming available across the EU will provide a glimmer of hope to over 380,000 people in Europe this year who have received the devastating news that they have lung cancer. Not only has Tarceva demonstrated a striking survival benefit (42.5 per ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to treat or prevent human illnesses. E6020 is a chemically synthesized adjuvant that will be ...
Madrid (ots/PRNewswire) - Zeltia S.A. (ZEL SM; ZEL.MC), Spanish pioneer and leader in biotechnology, announces 9 months results to September 2005. Research and Development spend amounted to EUR31 million during this period, a 10% increase year on year. 83% of this amount was accounted for by PharmaMar. Notable advances at PharmaMar in the last quarter include ...
Basel, Switzerland (ots/PRNewswire) - Following today's European approval of Boehringer Ingelheim's boosted protease inhibitor tipranavir (APTIVUS(R)), European patients now have the chance to benefit from the potent combination of the fusion inhibitor FUZEON (enfuvirtide) and boosted tipranavir in addition to ...
Amsterdam, The Netherlands (ots/PRNewswire) - - Valdoxan(R) (agomelatine) Provides Antidepressant Efficacy With the Additional Clinical Benefit of Sleep Improvement With no Effect on Daytime Vigilance The first melatonergic antidepressant, Valdoxan(R) (agomelatine), offers an innovative new approach to the treatment of depression. Valdoxan combines ...
Amsterdam, The Netherlands (ots/PRNewswire) - - New data also demonstrate SEROQUEL tolerability benefits versus other atypicals in schizophrenia and reinforce therapeutic potential in bipolar disorder Seroquel (quetiapine), olanzapine and risperidone are equally effective in patients experiencing first episode psychosis, according to data presented today ...
Alderley Park, England (ots/PRNewswire) - - For Health Professional Press and Non-UK Journalists Only Newly released top-line results from the BOLDER II (BipOLar DEpRession) study have underlined the potential for SEROQUEL (quetiapine fumarate) in the treatment of patients with major depressive episodes associated with bipolar disorder. In BOLDER ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the third quarter ended September 30, 2005, proudly reporting net income of US$19.8 million, compared to a net loss of US$21.4 million in the 2004 third quarter. Worldwide sales of Cialis(R) (tadalafil)(1) in the third quarter of 2005 totaled US$195.1 million, ...
Berlin, Germany (ots/PRNewswire) - - For Healthcare Professional Journalists - Not for distribution to US media - Randomised, Placebo-Controlled Study Shows Discontinuation of Pramipexole Leads to Rapid Worsening of Symptoms - Two new, randomised, placebo-controlled studies presented this week at the ...
Basel, Switzerland (ots/PRNewswire) - - New potent combinations make suppression of virus to undetectable levels more achievable for treatment-experienced HIV patients The importance of the drug FUZEON(R) (enfuvirtide) in the management of HIV has been officially recognised by the US Department of Health ...
World Federation for Mental Health
Washington D.c. (ots/PRNewswire) - - Dr Benedetto Saraceno of WHO Will Keynote a Symposium to Mark 2005 WMHD in Washington D.C. The 13th World Mental Health Day (WMHD) will be celebrated today in many countries and this year examines the close relationship between mental and physical health across all ...
Cheshire, England (ots/PRNewswire) - ATTN: Health Press Most people with bipolar disorder believe that successful treatment would significantly improve their quality of life and that treatment satisfaction is achieved by efficacy and tolerability, according to final results from the large scale Thinking ...
London (ots/PRNewswire) - - Takeda's ACTOS(R) (pioglitazone HCl) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS(R) (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk ...
Dar Es Salaam, Tanzania (ots/PRNewswire) - - The Abbott Fund and the Government of Tanzania Dedicate New Hospital Facilities to Meet Long-Term Needs of Patients with HIV/AIDS and Other Diseases In a ceremony today, Abbott CEO Miles White joined Tanzanian President Benjamin William Mkapa in dedicating a ...
Indianapolis and Ingelheim, Germany (ots/PRNewswire) - Your mother, your friend, your sister - chances are one of these three women have suffered from the symptoms of stress urinary incontinence (SUI), but she has been too embarrassed to admit it. This is just one of the staggering facts revealed by a ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. ("Isotechnika") and Atrium Medical Corporation ("Atrium") jointly announced today the signing of an exclusive worldwide licensing agreement for the use of TAFA93 and ISA247 specifically with drug eluting ...
Lyon, France et Swiftwater, Pennsylvanie (ots/PRNewswire) - - First Combination Vaccine Candidate in the U.S. Designed to Protect Infants and Young Children against Diphtheria, Tetanus, Pertussis, Polio, and Hib Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN), (NYSE: SNY), announced today the acceptance of a Biologics ...
Munich, Germany (ots/PRNewswire) - - Longer Storage Period Makes Platelets More Readily Available to European Transfusion Blood Centers European subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have received CE Mark Certification from TÜV Product Service GmbH extending the storage period ...
Brussels, Belgium (ots/PRNewswire) - Today UCB announced that the European Commission has approved the use of Keppra(R) (levetiracetam) in the European Union, as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in children from four to sixteen years of ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today the unblinded 12 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A Summary of the results is as follows: - The study met all primary and secondary efficacy endpoints determined at 12 weeks - Efficacy endpoints were achieved with minimal side effects - No clinically ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Influenza Vaccine Leader Takes New Step in Global Pandemic Preparedness LYON, France and SWIFTWATER, Pennsylvania, September 15 /PRNewswire/ -- Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an ...
Madrid (ots/PRNewswire) - - Further Steps in the Development of Aplidin(R) in Melanoma in First Line Therapy PharmaMar announces the initiation of a programme of combination studies with Aplidin(R) (plitidepsin), PharmaMar's novel marine-derived anti-tumour agent, originally isolated from the tunicate Aplidium albicans. Aplidin(R) in Combination with Dacarbazine (DTIC) The first study is a Phase I/II ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the participation level in its Canadian Phase III psoriasis extension trial for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to discontinue ...
Athens, Greece (ots/PRNewswire) - Landmark data from the PROactive Study, presented today at the 41st meeting of the European Association for the Study of Diabetes (EASD) demonstrated that ACTOS(R) (pioglitazone HCl) significantly reduces the combined risk of heart attacks, strokes and death by 16% in high risk ...
Athens, Greece (ots/PRNewswire) - - 80 percent of diabetes patients in study preferred inhaled insulin system to mealtime injections Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today presented detailed results from a Phase 2 clinical study of inhaled insulin in people with type 1 ...